Imricor Medical Systems Management
Management criteria checks 4/4
Imricor Medical Systems' CEO is Steve Wedan, appointed in May 2006, has a tenure of 18.58 years. total yearly compensation is $464.90K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 1.88% of the company’s shares, worth A$5.21M. The average tenure of the management team and the board of directors is 6.4 years and 5.6 years respectively.
Key information
Steve Wedan
Chief executive officer
US$464.9k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 18.6yrs |
| CEO ownership | 1.9% |
| Management average tenure | 6.4yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now
May 08
Does Imricor Medical Systems (ASX:IMR) Have A Healthy Balance Sheet?
Jun 17Here's Why Imricor Medical Systems (ASX:IMR) Must Use Its Cash Wisely
Jul 08Will Imricor Medical Systems (ASX:IMR) Spend Its Cash Wisely?
Mar 23We're Hopeful That Imricor Medical Systems (ASX:IMR) Will Use Its Cash Wisely
May 09When Will Imricor Medical Systems, Inc. (ASX:IMR) Turn A Profit?
Feb 28We Think Imricor Medical Systems (ASX:IMR) Needs To Drive Business Growth Carefully
Jan 24What Is The Ownership Structure Like For Imricor Medical Systems, Inc. (ASX:IMR)?
Dec 02
What You Need To Know About Imricor Medical Systems, Inc.'s (ASX:IMR) Investor Composition
Aug 18Analysts Expect Breakeven For Imricor Medical Systems, Inc. (ASX:IMR)
Jun 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$20m |
| Mar 31 2024 | n/a | n/a | -US$21m |
| Dec 31 2023 | US$465k | US$465k | -US$23m |
| Sep 30 2023 | n/a | n/a | -US$20m |
| Jun 30 2023 | n/a | n/a | -US$17m |
| Mar 31 2023 | n/a | n/a | -US$17m |
| Dec 31 2022 | US$465k | US$465k | -US$17m |
| Sep 30 2022 | n/a | n/a | -US$18m |
| Jun 30 2022 | n/a | n/a | -US$20m |
| Mar 31 2022 | n/a | n/a | -US$20m |
| Dec 31 2021 | US$577k | US$464k | -US$20m |
| Sep 30 2021 | n/a | n/a | -US$18m |
| Jun 30 2021 | n/a | n/a | -US$17m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$565k | US$452k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$13m |
| Jun 30 2020 | n/a | n/a | -US$14m |
| Mar 31 2020 | n/a | n/a | -US$14m |
| Dec 31 2019 | US$349k | US$349k | -US$13m |
Compensation vs Market: Steve's total compensation ($USD464.90K) is below average for companies of similar size in the Australian market ($USD689.59K).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
CEO
Steve Wedan (55 yo)
18.6yrs
Tenure
US$464,900
Compensation
Mr. Steven Wedan, also known as Steve, has been the Chief Executive Officer, President and Director of Imricor Medical Systems Inc. since May 23, 2006 and serves as its Executive Chairman. Mr. Wedan has me...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 18.6yrs | US$464.90k | 1.88% A$ 5.2m | |
| CFO & VP of Finance | 2.4yrs | US$259.38k | no data | |
| Chief Operating Officer | 17.9yrs | US$315.00k | no data | |
| Vice President of Global Sales | 6.9yrs | no data | no data | |
| Vice President of Marketing & Business Development | 5.9yrs | no data | no data | |
| Company Secretary & Local Agent | 5.7yrs | no data | no data |
6.4yrs
Average Tenure
Experienced Management: IMR's management team is seasoned and experienced (6.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 18.6yrs | US$464.90k | 1.88% A$ 5.2m | |
| Independent Non-Executive Director | 3.8yrs | US$75.00k | 0.13% A$ 362.0k | |
| Independent Non-Executive Director | 5.6yrs | US$80.00k | 0.32% A$ 894.9k | |
| Independent Deputy Chairman & Lead Independent Director | 10.3yrs | US$80.00k | 2.31% A$ 6.4m | |
| Non-Independent Non-Executive Director | less than a year | no data | 0.091% A$ 251.9k |
5.6yrs
Average Tenure
57yo
Average Age
Experienced Board: IMR's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 23:46 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Imricor Medical Systems, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Elyse Shapiro | Bell Potter |
| Sarah Mann | MA Moelis Australia Securities Pty Ltd |
| Scott Power | Morgans Financial Limited |